Posted inDiabetes & Endocrinology news
Retatrutide: A Breakthrough Triple Agonist for Obesity and Type 2 Diabetes Management
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profile in the phase 3 TRIUMPH-2 trial.


















